Search Results
Department of Endocrinology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
Search for other papers by Lucia Russo in
Google Scholar
PubMed
Search for other papers by Thi Ngoc Huyen Nguyen in
Google Scholar
PubMed
Search for other papers by Aglaia Kyrilli in
Google Scholar
PubMed
Search for other papers by Martin Robin in
Google Scholar
PubMed
Search for other papers by Pierre Bel Lassen in
Google Scholar
PubMed
Search for other papers by Rodrigo Moreno-Reyes in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
Objective: Endogenous subclinical hyperthyroidism (eSCH) is defined by subnormal serum thyroid-stimulating hormone (TSH) level. There is limited evidence of metabolic changes induced by eSCH. The aim of our work was to evaluate changes in BMI and lipid parameters after radioiodine treatment in patients with grade 1 (TSH: 0.1–0.39 mlU/L) and 2 (TSH <0.1 mlU/L) eSCH. Design: A retrospective study was performed on 74 patients with eSCH caused by benign autonomous nodular goiter which was treated with radioiodine. Methods: We assessed BMI, lipids parameters, and TSH after radioiodine therapy. The 12-month follow-up time point was used to compare the primary outcome variables. TSH was measured by the electrochemiluminescence method. Results: After radioiodine therapy, the absolute and relative increases in BMI at 12 months were significantly higher in the grade 2 group than in the grade 1 group (1.07 ± 0.27 kg/m<sup>2</sup> vs. 0.26 ± 0.15 kg/m<sup>2</sup>, respectively; p = 0.023 and 4.01 ± 0.98% vs. 1.01 ± 0.56%, respectively; p = 0.026). Compared to baseline, significant increases in the levels of total cholesterol and LDL were observed after treatment in the grade 2 eSCH group (16.7 ± 4.5 mg/dL p < 0.01 and 14.3 ± 4.1 mg/dL p < 0.01, respectively) but not in the grade 1 group. In a multivariate model, a negative correlation was observed between pretreatment TSH levels and absolute BMI gain (p < 0.01). Conclusions: After correction of eSCH, increases in BMI and LDL levels were observed only in patients with grade 2 eSCH. Pretreatment serum TSH was the main independent factor associated with BMI changes after radioiodine treatment.
Search for other papers by Rodrigo Moreno-Reyes in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Agnieszka Piekiełko-Witkowska in
Google Scholar
PubMed
Search for other papers by Adriana Gaspar da Rocha in
Google Scholar
PubMed
Search for other papers by Corin Badiu in
Google Scholar
PubMed
Search for other papers by Josef Köhrle in
Google Scholar
PubMed
Search for other papers by Leonidas Duntas in
Google Scholar
PubMed
Graphical abstract
Abstract
In 2022, the European Chemicals Agency (ECHA) made a statement concluding that iodine is an endocrine disruptor (ED). We stress the fact that the ECHA opinion ECHA/BPC/357/2022 is based on their misguidedly zooming in on exclusively the biocidal products (e.g. hand disinfectants, disinfection of animals’ teats/udder, embalming fluids before cremation) that contain molecular iodine (I2), entirely neglecting the 2013 ECHA Regulation (EU) no. 528/2012 describing iodine as being of ‘great importance for human health’. Clearly, the current sweeping and erroneous classification of ‘iodine’ as an endocrine disruptor is ill-advised. We moreover call upon the scientific and medical community at large to use the accurate scientific nomenclature, i.e. iodide or iodate instead of ‘iodine’ when referring to iodized salts and food prepared there with. Drugs, diagnostic agents, and synthetic chemicals containing the element iodine in the form of covalent bonds must be correctly labeled ‘iodinated’, if possible, using each time their distinctive and accurate chemical or pharmacological name.
Search for other papers by Aglaia Kyrilli in
Google Scholar
PubMed
Search for other papers by Nunzia Tacelli in
Google Scholar
PubMed
Search for other papers by Lucia Russo in
Google Scholar
PubMed
Search for other papers by Laetitia Lebrun in
Google Scholar
PubMed
Search for other papers by Isabelle Salmon in
Google Scholar
PubMed
Search for other papers by Gilles Russ in
Google Scholar
PubMed
Search for other papers by Rodrigo Moreno-Reyes in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
Objectives
The aim was to evaluate the clinical, ultrasound (US) and, when indicated, the cytological and histological characteristics of autonomously functioning thyroid nodules (AFTN) in consecutive patients.
Methods
A prospective, single-centre study was conducted between March 2018 and September 2021. In total, 901 consecutive patients were referred for thyroid workup and of 67 AFTN were evaluated. All enrolled patients underwent 99mTcO4 − scintigraphy, additional 123I scintigraphy only in case of normal serum TSH, evaluation of thyroid function, US examination using European Thyroid Imaging and Reporting Data System (EU-TIRADS), and US-guided fine needle aspiration (FNA) cytology when indicated. All indeterminate FNA samples were subjected to DNA sequencing analysis.
Results
More than half of the evaluated patients with AFTN were euthyroid; median serum TSH was 0.41 (IQR: 0.03–0.97) mU/L. The median AFTN size measured by US was 27.0 (IQR: 21.1–35.0) mm. 28.4% of AFTN were classified as EU-TIRADS score 3 and 71.6% as EU-TIRADS score 4, indicating that the majority of AFTN had intermediate risk for malignancy according to US. Out of the 47 AFTN subjected to cytological evaluation, 24 (51%) yielded indeterminate FNA results. DNA sequencing revealed pathogenic TSHR and GNAS mutations in 60% of cases. No malignancy was detected at final histology in surgically excised AFTN (n = 12).
Conclusions
Of the 67 AFTN evaluated in this study, 50% presented with normal serum TSH, 70% displayed ultrasound features suggesting an intermediate malignancy risk and 50% of the AFTN submitted to cytology yielded indeterminate results. No malignant AFTN was detected.
